Главная
Study mode:
on
1
Current and Evolving Understanding in Hypertrophic Cardiomyopa
2
Hypertrophic Cardiomyopathy: Some simple math
3
Step 1: Multimodality imaging key in diagnosing HCM
4
Recognition of Apical aneurysms
5
LV Strain
6
NIH Sponsored HCMR Registry
7
Machine learning. LV shape and insights into pathophysiology
8
AI, EKG, HCM
9
Machine learning and HCM
10
Elicit LVOT Obstruction: Don't look, Won't find, Can't Tre
11
Stress Echo
12
Recognize typical and atypical variants of obstructive HC OCM without the H: Abnormal mitral subvalvular morphology
13
3 different flavors of "Atypical" LVOT obstruction
14
Differential diagnosis using multimodality imaging
15
Important to make the correct diagnosis
16
SCD risk stratification
17
Comparison of ESC vs. American Approach
18
ICD placement
19
HCM LGE Outcomes
20
Screening Echo vs. CMR in G+P-patients
21
Management in oHCM
22
Lifestyle considerations
23
Vigorous exercise and HCM: LIVE-HCM Trial
24
In oHCM, there are no prospective RCT (single or multicenter) compar a various FDA-approved medical therapies b invasive therapies vs. FDA-approved medical Rx c myectomy vs. alcohol ablation
25
Septal Reduction Therapy: One operation does not fit
26
Cleveland Clinic approach to Surgical LVOT obstructi
27
Alcohol septal ablation
28
Guidelines: Invasive therapies
29
Spectrum of oHCM management in USA
30
Expert Centers Have Markedly Better SRT Outcomes But Access to Specialty Centers Are Limited
31
Mavacamten Prevents Disease Phenotype in HCM Mice
32
Phase III RCTs: Testing Mavacamten vs. Placebo EXPLORER-HCM vs. VALOR-HCM
33
Mavacamten LTE study
34
Valor-HCM: 92% NYHA Class III 19 US HCM Centers
35
Primary endpoint and NYHA Class Improvement
36
Secondary Efficacy Endpoints
37
Favorable Cardiac Remodeling
38
A VALOR Mavacamten Story
39
LVEF and mavacamten: Implications in clinical practice
40
Clinical management of Camzyos (Mavacamten)
41
Gene-therapy: Adeno-associated Virus mediated
42
These new therapies are going to bring new logistic scenarios, assum long-term safety and efficacy
43
Symptomatic Nonobstructive HCM
44
Managing Arrhythmias Atrial fibrillation: A Bad Actor in HCM, especially oHCM
45
Management of AF
46
Genetic Testing in HCM
47
Genetics and long-term outcomes: SHARE registry!
48
Screening of asymptomatic first-degree relativ EKG and echo
49
Valsartan in Early Stage HCM: VANISH Trial
Description:
Explore the latest developments in hypertrophic cardiomyopathy (HCM) through this comprehensive cardiology grand rounds lecture. Delve into multimodality imaging techniques for accurate HCM diagnosis, including recognition of apical aneurysms and LV strain analysis. Learn about the NIH-sponsored HCMR Registry and the application of machine learning and AI in HCM research. Understand the importance of eliciting left ventricular outflow tract (LVOT) obstruction and recognizing typical and atypical variants of obstructive HCM. Examine sudden cardiac death risk stratification, comparing ESC and American approaches to ICD placement. Discover management strategies for obstructive HCM, including lifestyle considerations and the LIVE-HCM Trial on vigorous exercise. Explore septal reduction therapies, including surgical approaches and alcohol septal ablation. Gain insights into new pharmacological treatments, such as Mavacamten, and their impact on disease phenotype and cardiac remodeling. Discuss gene therapy prospects and the management of arrhythmias in HCM patients. Finally, learn about genetic testing, long-term outcomes from the SHARE registry, and screening protocols for asymptomatic first-degree relatives. Read more

Current and Evolving Understanding in Hypertrophic Cardiomyopathy - Cardiology Grand Rounds

MonteHeart Lectures
Add to list
#Health & Medicine #Health Care #Cardiology #Computer Science #Artificial Intelligence #Machine Learning #Radiology #Medical Imaging #Multimodality Imaging
0:00 / 0:00
1 of 49

Current and Evolving Understanding in Hypertrophic Cardiomyopa